Free tool
FAERS Monitor: Zykadia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211225 or its brand name (Zykadia, Ceritinib). Reports on generic versions are filed under their own applications.
Reports
2,384
Serious
1,941
81% of reports
Hospitalization
589
Death reported
553
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malignant neoplasm progression430
- diarrhoea427
- nausea343
- death281
- vomiting224
- metastases to central nervous system172
- fatigue134
- non-small cell lung cancer130
- decreased appetite119
- disease progression112
- dyspnoea102
- abdominal pain100
- asthenia90
- non-small cell lung cancer stage iv90
- drug ineffective85
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2014 | 98 |
| 2015 | 332 |
| 2016 | 371 |
| 2017 | 311 |
| 2018 | 312 |
| 2019 | 182 |
| 2020 | 182 |
| 2021 | 221 |
| 2022 | 183 |
| 2023 | 91 |
| 2024 | 53 |
| 2025 | 29 |
| 2026 | 17 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,775 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| non-small cell lung cancer stage ivSignal | 90 | 2900.5 | 2293.7 | 194,193 |
| non-small cell lung cancerSignal | 130 | 246.1 | 207.7 | 30,639 |
| metastases to central nervous systemSignal | 172 | 119.2 | 103.1 | 19,792 |
| malignant neoplasm progressionSignal | 430 | 37.2 | 34.1 | 15,120 |
| disease progressionSignal | 112 | 8.4 | 7.0 | 722 |
| diarrhoeaSignal | 427 | 5.8 | 5.4 | 1,761 |
| decreased appetiteSignal | 119 | 4.5 | 3.8 | 326 |
| vomitingSignal | 224 | 4.2 | 3.7 | 556 |
| nauseaSignal | 343 | 3.8 | 3.5 | 740 |
| abdominal painSignal | 100 | 3.8 | 3.1 | 205 |
| deathSignal | 281 | 2.9 | 2.6 | 357 |
| astheniaSignal | 90 | 2.1 | 1.7 | 53 |
| dyspnoea | 102 | 1.6 | 1.3 | 22 |
| fatigue | 134 | 1.5 | 1.3 | 24 |
| drug ineffective | 85 | 0.6 | 0.5 | 29 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.